 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...109110111112113114115116117118119...143144» |
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P2 data, Journal: A phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity modulated radiation therapy (IMRT) for patients with stage III/IVB head and neck squamous cell carcinoma (HNSCC). (Pubmed Central) - Mar 4, 2018
With a median follow up of 33.8 months, 2 year PFS was 88.5% (95% CI, 68.1-96.1) and 2 year OS was 92.8% (95% CI, 74.2-98.1%) Conclusion. The addition of bevacizumab and cetuximab to two cycles of cisplatin, given concurrently with IMRT, was well tolerated and was associated with favorable efficacy outcomes in this patient population.
- | dexamethasone / Generic mfg., floxuridine / Generic mfg.
Trial initiation date, Combination therapy, Metastases: Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver (clinicaltrials.gov) - Mar 3, 2018
P2, N=40, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
The addition of bevacizumab and cetuximab to two cycles of cisplatin, given concurrently with IMRT, was well tolerated and was associated with favorable efficacy outcomes in this patient population. Initiation date: Mar 2018 --> Mar 2018
- ||||| linrodostat (BMS-986205) / BMS, Ono Pharma, Opdivo (nivolumab) / BMS
Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy, Metastases: An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck (clinicaltrials.gov) - Mar 3, 2018
P3, N=580, Not yet recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Mar 2018 --> Mar 2018 Trial completion date: Aug 2024 --> Sep 2024 | Initiation date: Feb 2018 --> Mar 2018 | Trial primary completion date: Jul 2021 --> Aug 2021
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: CheckMate 651: Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Mar 3, 2018
P3, N=700, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Aug 2024 --> Sep 2024 | Initiation date: Feb 2018 --> Mar 2018 | Trial primary completion date: Jul 2021 --> Aug 2021 Trial completion date: Mar 2020 --> Dec 2020 | Trial primary completion date: Jan 2019 --> Feb 2019
- || patritumab (U3-1287) / Amgen, Daiichi Sankyo
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN ) (clinicaltrials.gov) - Mar 3, 2018
P2, N=87, Active, not recruiting, Sponsor: Daiichi Sankyo, Inc.
Trial completion date: Mar 2020 --> Dec 2020 | Trial primary completion date: Jan 2019 --> Feb 2019 Trial completion date: May 2018 --> Feb 2018 | Trial primary completion date: Feb 2018 --> Jan 2018
- || simlukafusp alfa (RG7461) / Roche, Herceptin (trastuzumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy: A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) (clinicaltrials.gov) - Mar 3, 2018
P1a/1b, N=180, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: May 2018 --> Feb 2018 | Trial primary completion date: Feb 2018 --> Jan 2018 Trial completion date: Jul 2019 --> Aug 2019 | Trial primary completion date: Jul 2019 --> Aug 2019
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Metastases: Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). (clinicaltrials.gov) - Mar 3, 2018
P2, N=27, Active, not recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
Trial completion date: Jul 2019 --> Aug 2019 | Trial primary completion date: Jul 2019 --> Aug 2019 Trial completion date: Dec 2017 --> Jun 2018
- | Votrient (pazopanib) / Novartis, BeiGene, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date: Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Mar 3, 2018
P1, N=32, Active, not recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Dec 2017 --> Jun 2018 Trial completion date: Dec 2017 --> May 2018
- | merestinib (LY2801653) / Eli Lilly
Trial completion date, Metastases: A Study of LY2801653 in Advanced Cancer (clinicaltrials.gov) - Mar 3, 2018
P1, N=190, Completed, Sponsor: Eli Lilly and Company
Trial completion date: Dec 2017 --> May 2018 Trial completion date: Sep 2017 --> Sep 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Metastases: Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Mar 3, 2018
P2, N=128, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Sep 2017 --> Sep 2017 Trial completion date: Jul 2019 --> Jul 2020
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: TROG 12.01: Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (clinicaltrials.gov) - Feb 28, 2018
P3, N=200, Recruiting, Sponsor: Trans-Tasman Radiation Oncology Group (TROG)
Trial completion date: Jul 2019 --> Jul 2020 Trial primary completion date: Jun 2019 --> Jun 2020 | Trial completion date: Jun 2021 --> Jun 2022 | Initiation date: Jun 2013 --> Jun 2013
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial completion date, Metastases: Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Feb 26, 2018
P2, N=24, Completed, Sponsor: Fox Chase Cancer Center
Trial primary completion date: Jun 2019 --> Jun 2020 | Trial completion date: Jun 2021 --> Jun 2022 | Initiation date: Jun 2013 --> Jun 2013 Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Oct 2017
- ||||| Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: LCCC1717: Palbociclib and Cetuximab in Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 25, 2018
P2, N=57, Not yet recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Journal: Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer. (Pubmed Central) - Feb 25, 2018
Platin and cetuximab seem to have similar efficacy when delivered concurrently with radiation in our retrospective population study. Although platin did cause greater hematologic toxicity, radiation-specific side effects seemed relatively comparable.
- || Biomarker, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker, Metastases: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Feb 23, 2018
P2, N=1400, Recruiting, Sponsor: Hoffmann-La Roche
Although platin did cause greater hematologic toxicity, radiation-specific side effects seemed relatively comparable. Trial primary completion date: Oct 2020 --> May 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Clinical, Journal: Increased PD-1+ and TIM-3+ TILs during cetuximab therapy inversely correlates with response in head and neck cancer patients. (Pubmed Central) - Feb 22, 2018
These findings support the use of PD-1 and TIM-3 as biomarkers to reflect immune status of CD8+ T cells in the tumor microenvironment during cetuximab therapy. Blockade of these immune checkpoint receptors might enhance cetuximab-based cancer immunotherapy to reverse CD8+ TIL dysfunction, thus potentially improving clinical outcomes of HNSCC patients.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux (clinicaltrials.gov) - Feb 19, 2018
P3, N=406, Active, not recruiting, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
Blockade of these immune checkpoint receptors might enhance cetuximab-based cancer immunotherapy to reverse CD8+ TIL dysfunction, thus potentially improving clinical outcomes of HNSCC patients. Trial primary completion date: Dec 2017 --> Dec 2018
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: TPExtreme: Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC (clinicaltrials.gov) - Feb 19, 2018
P2, N=416, Active, not recruiting, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2017 --> Dec 2018
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: FAMOSO: Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District (clinicaltrials.gov) - Feb 19, 2018
P2, N=10, Recruiting, Sponsor: European Institute of Oncology
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2018 --> Dec 2019
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Surgery, Metastases: BOND-3: Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Feb 14, 2018
P2, N=60, Active, not recruiting, Sponsor: Academic and Community Cancer Research United
Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2018 --> Dec 2019 Recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, cetuximab biosimilar / CinnaGen
Trial completion date, Trial primary completion date, Metastases: Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux (clinicaltrials.gov) - Feb 14, 2018
P3, N=234, Recruiting, Sponsor: Cinnagen
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2018 --> Nov 2019 | Trial completion date: Nov 2018 --> Feb 2020
- | fosifloxuridine nafalbenamide (NUC-3373) / NuCana
New P1 trial, Combination therapy: NuTide:302: A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment (clinicaltrials.gov) - Feb 12, 2018
P1, N=62, Not yet recruiting, Sponsor: NuCana plc
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience. (Pubmed Central) - Feb 11, 2018
Patients with resected high-risk SCCHN treated with postoperative cetuximab and radiation have suboptimal therapeutic outcomes. Further study of the efficacy and cost-effectiveness compared to radiation alone is warranted.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: IL-21 enhances natural killer cell response to cetuximab-coated pancreatic tumor cells. (Pubmed Central) - Feb 10, 2018
These results suggest that cetuximab treatment in combination with IL-21 adjuvant therapy in patients with EGFR-positive pancreatic cancer results in significant NK cell activation, irrespective of KRAS mutation status, and may be a potential therapeutic strategy. Clin Cancer Res; 23(2); 489-502.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim, erlotinib / Generic mfg.
Preclinical, Journal: EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models. (Pubmed Central) - Feb 10, 2018
In response to erlotinib, these dendritic cells and macrophages had significantly higher MHC class II expression, indicating increased antigen-presenting capabilities. Together, results of our study provide novel insight into the immediate-early therapeutic response to EGFR TKIs in vivo.
- | Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Journal: nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma. (Pubmed Central) - Feb 9, 2018
Together, results of our study provide novel insight into the immediate-early therapeutic response to EGFR TKIs in vivo. This phase II trial demonstrated favorable two-year DSS, PFS, and OS and a low relapse rate in HPV-unrelated HNSCC and HPV-related OPSCC treated with APF followed by CRT.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Trial initiation date, Surgery: SULTAN: Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network (clinicaltrials.gov) - Feb 8, 2018
P2, N=140, Not yet recruiting, Sponsor: UNICANCER
This phase II trial demonstrated favorable two-year DSS, PFS, and OS and a low relapse rate in HPV-unrelated HNSCC and HPV-related OPSCC treated with APF followed by CRT. Initiation date: Nov 2017 --> May 2018
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Imfinzi (durvalumab) / AstraZeneca
Enrollment open, PD(L)-1 Biomarker, Metastases: NRG-HN004: Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin (clinicaltrials.gov) - Feb 8, 2018
P2/3, N=533, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Nov 2017 --> May 2018 Not yet recruiting --> Recruiting
- ||| FATE-NK100 / Fate Therap
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Feb 8, 2018
P1, N=100, Recruiting, Sponsor: Fate Therapeutics
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2018 --> Mar 2019 | Trial completion date: Dec 2020 --> Mar 2020 | Initiation date: Nov 2017 --> Jan 2018
- | Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, Surgery, Metastases: Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Feb 7, 2018
P1/2, N=42, Recruiting, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2018 --> Mar 2019 | Trial completion date: Dec 2020 --> Mar 2020 | Initiation date: Nov 2017 --> Jan 2018 Trial primary completion date: Jan 2018 --> Jan 2019 | Trial completion date: Jan 2018 --> Jan 2020
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Trial completion date, Trial primary completion date: Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab (clinicaltrials.gov) - Feb 6, 2018
P=N/A, N=40, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Jan 2018 --> Jan 2019 | Trial completion date: Jan 2018 --> Jan 2020 Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2017 --> Dec 2018
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Mismatch repair, Metastases: Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) (clinicaltrials.gov) - Feb 6, 2018
P3, N=300, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2017 --> Dec 2018 Recruiting --> Active, not recruiting
- ||| tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Enrollment closed, Enrollment change, Trial primary completion date: An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols (clinicaltrials.gov) - Feb 5, 2018
P1/2, N=60, Active, not recruiting, Sponsor: ArQule
Recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting | N=50 --> 60 | Trial primary completion date: Dec 2017 --> Dec 2018
- || Ojemda (tovorafenib) / Day One Biopharma, alisertib (MLN8237) / Puma
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies (clinicaltrials.gov) - Feb 5, 2018
P1b, N=125, Active, not recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Enrolling by invitation --> Active, not recruiting | N=50 --> 60 | Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Sep 2019 | Trial completion date: Dec 2017 --> Sep 2019
- ||| Ibrance (palbociclib) / Pfizer
Enrollment closed, Trial primary completion date, Metastases: PALATINUS: Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer (clinicaltrials.gov) - Feb 5, 2018
P2, N=112, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Sep 2019 | Trial completion date: Dec 2017 --> Sep 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2018 --> Aug 2018
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Verzenio (abemaciclib) / Eli Lilly
Enrollment open, Trial initiation date, Monotherapy, Metastases: ABORL: Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 (clinicaltrials.gov) - Feb 5, 2018
P2, N=25, Recruiting, Sponsor: Centre Leon Berard
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2018 --> Aug 2018 Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Feb 2018
- |||||| epacadostat (INCB024360) / Incyte
Enrollment open, Combination therapy, Metastases: Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) (clinicaltrials.gov) - Feb 5, 2018
P3, N=550, Recruiting, Sponsor: Incyte Corporation
Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Feb 2018 Not yet recruiting --> Recruiting
- | ficlatuzumab (AV-299) / LG Chem, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: P30CA023074: Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Feb 5, 2018
P2, N=74, Recruiting, Sponsor: University of Arizona
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Journal: Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. (Pubmed Central) - Feb 2, 2018
Not yet recruiting --> Recruiting The combination of bevacizumab, cetuximab, and temsirolimus showed activity in HNSCC; however, there were numerous toxicities reported, which will require careful management for future clinical development.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Trial completion, Trial primary completion date, Metastases: Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab (clinicaltrials.gov) - Jan 31, 2018
P2, N=19, Completed, Sponsor: Academic and Community Cancer Research United
The combination of bevacizumab, cetuximab, and temsirolimus showed activity in HNSCC; however, there were numerous toxicities reported, which will require careful management for future clinical development. Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> May 2014
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Phase classification, Trial primary completion date: Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients (clinicaltrials.gov) - Jan 30, 2018
P2, N=100, Recruiting, Sponsor: University of Louisville
Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> May 2014 Phase classification: P1 --> P2 | Trial primary completion date: Aug 2018 --> Aug 2019
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 (clinicaltrials.gov) - Jan 30, 2018
P1/2, N=30, Recruiting, Sponsor: Weill Medical College of Cornell University
Phase classification: P1 --> P2 | Trial primary completion date: Aug 2018 --> Aug 2019 Trial primary completion date: Jan 2018 --> Jan 2019
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, cetuximab biosimilar / CinnaGen
Enrollment open, Metastases: Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux (clinicaltrials.gov) - Jan 30, 2018
P3, N=234, Recruiting, Sponsor: Cinnagen
Trial primary completion date: Jan 2018 --> Jan 2019 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Trial primary completion date, Metastases: Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design (clinicaltrials.gov) - Jan 29, 2018
P2, N=160, Recruiting, Sponsor: Dwight Heron
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2017 --> Dec 2020
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN (clinicaltrials.gov) - Jan 29, 2018
P2, N=92, Recruiting, Sponsor: University of Pittsburgh
Trial primary completion date: Dec 2017 --> Dec 2020 Trial primary completion date: Dec 2017 --> Dec 2019
- || napabucasin (BBI608) / Sumitomo Pharma
Trial primary completion date, Metastases: A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Jan 24, 2018
P2, N=150, Active, not recruiting, Sponsor: Boston Biomedical, Inc
Trial primary completion date: Dec 2017 --> Dec 2019 Trial primary completion date: Dec 2017 --> Dec 2018
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: CTXMAB+RT: Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Jan 17, 2018
P2, N=70, Terminated, Sponsor: Azienda USL 4 Prato
Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Dec 2019 --> May 2015
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New trial, Tumor mutational burden, Metastases: The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment (clinicaltrials.gov) - Jan 16, 2018
P=N/A, N=120, Recruiting, Sponsor: National Health Research Institutes, Taiwan
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, Trial primary completion date, Metastases: Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab (clinicaltrials.gov) - Jan 12, 2018
P2, N=10, Terminated, Sponsor: University of California, Irvine
Trial primary completion date: Dec 2019 --> May 2015 N=44 --> 10 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2009 --> May 2009; slow accrual
- || simlukafusp alfa (RG7461) / Roche, Herceptin (trastuzumab) / Roche
Phase classification, Enrollment change, Combination therapy: A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) (clinicaltrials.gov) - Jan 11, 2018
P1a/1b, N=180, Recruiting, Sponsor: Hoffmann-La Roche
N=44 --> 10 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2009 --> May 2009; slow accrual Phase classification: P1 --> P1a/1b | N=60 --> 180